|
1
Tenor, H., Hatzelmann, A., Church, M.K., et al. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol 118 1727-1735 (1996).
2
Souness, J.E., Griffin, M., Maslen, C., et al. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFa generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br J Pharmacol 118 649-658 (1996).
3
Sasaki, T., Kitagawa, K., Omura-Matsuoka, E., et al. The phosphodiesterase inhibitor rolipram promotes survival of newborn hippocampal neurons after ischemia. Stroke 38 1597-1605 (2007).
4
Kanes, S.J., Tokarczyk, J., Siegel, S.J., et al. Rolipram: A specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience 144 239-246 (2007).
5
Yao, W., Tian, X.Y., Chen, J., et al. Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats. J Musculoskelet Neuronal Interact 7(2) 119-130 (2007).
|